Payment overview · 2025
General Payments
$2,205.46
91 reported records · 20 companies
Healthcare provider profile · identity verified
Mikhail Chilingaryan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSBURGH, PA · NPI 1356581201
Verified facts
What the public records show
CMS Open Payments records show Mikhail Chilingaryan, MD received $2,205.46 in general payments during 2025 across 91 reported records.
ABBVIE INC. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 687 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 980 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 539 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ztlido by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $349.88 | 15.9% | 15 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $337.47 | 15.3% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $229.11 | 10.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.00 | 10.2% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.89 | 6.7% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $139.52 | 6.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $131.65 | 6.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $119.86 | 5.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $92.96 | 4.2% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.19 | 3.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.05 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.82 | 2.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.08 | 2.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $44.00 | 2.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.27 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.95 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.92 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.51 | 1.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.39 | 0.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.94 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,205.46 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $337.47 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $246.40 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $226.53 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $178.57 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.89 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $139.52 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.48 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.09 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $92.96 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $92.96 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.53 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $86.01 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $85.91 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.90 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.90 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.09 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $70.19 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.05 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.82 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.54 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.75 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.08 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.95 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 341 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 980 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 96 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 687 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 119 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 427 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 239 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
341 | 53 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
687 | 89 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
980 | 144 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
96 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
239 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
539 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
119 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
263 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
427 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 2811 | 328 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2151 | 267 |
| Hydralazine Hcl | Hydralazine Hcl | 1491 | 184 |
| Donepezil Hcl | Donepezil Hcl | 1431 | 169 |
| Meclizine Hcl | Meclizine Hcl | 1339 | 173 |
| Omeprazole | Omeprazole | 1323 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 1313 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1246 | 159 |
| Farxiga | Dapagliflozin Propanediol | 980 | 144 |
| Metformin Hcl | Metformin Hcl | 972 | 125 |
| Clonidine Hcl | Clonidine Hcl | 911 | 98 |
| Losartan Potassium | Losartan Potassium | 908 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 898 | 103 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 870 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 827 | 92 |
| Ibuprofen | Ibuprofen | 817 | 111 |
| Zolpidem Tartrate | Zolpidem Tartrate | 804 | 114 |
| Meloxicam | Meloxicam | 794 | 106 |
| Sertraline Hcl | Sertraline Hcl | 794 | 119 |
| Furosemide | Furosemide | 775 | 93 |
| Vascepa | Icosapent Ethyl | 756 | 115 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 730 | 110 |
| Glimepiride | Glimepiride | 700 | 94 |
| Linzess | Linaclotide | 687 | 89 |
| Fenofibrate | Fenofibrate | 686 | 80 |
| Ezetimibe | Ezetimibe | 669 | 76 |
| Diclofenac Sodium | Diclofenac Sodium | 659 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 643 | 72 |
| Lisinopril | Lisinopril | 607 | 80 |
| Carvedilol | Carvedilol | 562 | 61 |
| Jardiance | Empagliflozin | 539 | 70 |
| Nifedipine Er | Nifedipine | 500 | 82 |
| Icosapent Ethyl | Icosapent Ethyl | 485 | 96 |
| Lorazepam | Lorazepam | 469 | 52 |
| Metformin Er Gastric | Metformin Hcl | 439 | 55 |
| Dapagliflozin | Dapagliflozin Propanediol | 436 | 107 |
| Diflorasone Diacetate | Diflorasone Diacetate | 427 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 427 | 48 |
| Ozempic | Semaglutide | 427 | 57 |
| Celecoxib | Celecoxib | 392 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 386 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 386 | 68 |
| Alendronate Sodium | Alendronate Sodium | 381 | 39 |
| Dexlansoprazole Dr | Dexlansoprazole | 378 | 54 |
| Tramadol Hcl | Tramadol Hcl | 374 | 44 |
| Atenolol | Atenolol | 367 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 364 | 50 |
| Naproxen | Naproxen | 353 | 96 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 351 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 349 | 34 |
| Creon | Lipase/Protease/Amylase | 341 | 53 |
| Montelukast Sodium | Montelukast Sodium | 339 | 35 |
| Diclofenac Potassium | Diclofenac Potassium | 325 | 50 |
| Glipizide | Glipizide | 322 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 322 | 42 |
| Januvia | Sitagliptin Phosphate | 316 | 37 |
| Potassium Chloride | Potassium Chloride | 316 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 309 | 33 |
| Memantine Hcl Er | Memantine Hcl | 292 | 36 |
| Baclofen | Baclofen | 290 | 30 |
| Lidocaine | Lidocaine | 290 | 44 |
| Trazodone Hcl | Trazodone Hcl | 273 | 29 |
| Myrbetriq | Mirabegron | 270 | 34 |
| Trulicity | Dulaglutide | 263 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 35 |
| Finasteride | Finasteride | 247 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 246 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 239 | 40 |
| Colchicine | Colchicine | 236 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 235 | 27 |
| Azithromycin | Azithromycin | 227 | 155 |
| Allopurinol | Allopurinol | 225 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 215 | 20 |
| Propranolol Hcl | Propranolol Hcl | 215 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 215 | 32 |
| Famotidine | Famotidine | 210 | 27 |
| Repatha Sureclick | Evolocumab | 208 | 36 |
| Ketoconazole | Ketoconazole | 205 | 23 |
| Meloxicam | Meloxicam, Submicronized | 198 | 25 |
| Hydrocortisone | Hydrocortisone | 195 | 39 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 184 | 20 |
| Alprazolam | Alprazolam | 178 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 178 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 176 | 17 |
| Simvastatin | Simvastatin | 174 | 24 |
| Memantine Hcl | Memantine Hcl | 169 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 164 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 158 | 21 |
| Methimazole | Methimazole | 157 | 22 |
| Valsartan | Valsartan | 149 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 146 | 19 |
| Eliquis | Apixaban | 141 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 139 | 26 |
| Pitavastatin Calcium | Pitavastatin Calcium | 135 | 25 |
| Minoxidil | Minoxidil | 131 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 131 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 126 | 14 |
| Procto-Med Hc | Hydrocortisone | 124 | 18 |
| Clotrimazole | Clotrimazole | 122 | 24 |
| Nitroglycerin | Nitroglycerin | 121 | 22 |
| Mounjaro | Tirzepatide | 119 | 21 |
| Tavaborole | Tavaborole | 119 | 22 |
| Clonidine | Clonidine | 116 | 12 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 115 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 110 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 110 | 18 |
| Clonazepam | Clonazepam | 107 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 15 |
| Buspirone Hcl | Buspirone Hcl | 104 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 104 | 12 |
| Terazosin Hcl | Terazosin Hcl | 101 | suppressed |
| Aripiprazole | Aripiprazole | 100 | 12 |
| Bupropion Xl | Bupropion Hcl | 99 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 99 | 21 |
| Kerendia | Finerenone | 96 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 96 | 11 |
| Dutasteride | Dutasteride | 94 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 15 |
| Mirtazapine | Mirtazapine | 92 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 91 | 17 |
| Benazepril Hcl | Benazepril Hcl | 88 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 87 | 22 |
| Restasis | Cyclosporine | 87 | 12 |
| Spironolactone | Spironolactone | 84 | suppressed |
| Xarelto | Rivaroxaban | 84 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 82 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 79 | 23 |
| Fenofibrate | Fenofibrate,micronized | 79 | suppressed |
| Fluocinonide | Fluocinonide | 79 | 17 |
| Azelastine Hcl | Azelastine Hcl | 78 | suppressed |
| Cilostazol | Cilostazol | 77 | suppressed |
| Ramipril | Ramipril | 77 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 13 |
| Lansoprazole | Lansoprazole | 74 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 73 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 73 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 72 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 66 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 65 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 65 | suppressed |
| Entresto | Sacubitril/Valsartan | 64 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 64 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Glipizide Er | Glipizide | 59 | suppressed |
| Rybelsus | Semaglutide | 59 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 58 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 58 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 58 | suppressed |
| Levofloxacin | Levofloxacin | 57 | 50 |
| Incruse Ellipta | Umeclidinium Bromide | 55 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Rivastigmine | Rivastigmine | 53 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Cyclosporine | Cyclosporine | 52 | 12 |
| Olanzapine | Olanzapine | 52 | suppressed |
| Ranolazine Er | Ranolazine | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 45 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Novolog Flexpen | Insulin Aspart | 49 | 11 |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 46 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Ciclopirox | Ciclopirox | 44 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | suppressed |
| Repatha Syringe | Evolocumab | 43 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 42 | suppressed |
| Loperamide | Loperamide Hcl | 41 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 41 | suppressed |
| Calcipotriene | Calcipotriene | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Ibu | Ibuprofen | 40 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | 22 |
| Brilinta | Ticagrelor | 38 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Nystatin | Nystatin | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 33 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 34 | suppressed |
| Prednisone | Prednisone | 34 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 31 | suppressed |
| Niacin Er | Niacin | 31 | suppressed |
| Ofloxacin | Ofloxacin | 31 | 22 |
| Febuxostat | Febuxostat | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Lofena | Diclofenac Potassium | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 21 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Piroxicam | Piroxicam | 24 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 23 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Jublia | Efinaconazole | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Edarbi | Azilsartan Medoxomil | 21 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Gemtesa | Vibegron | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Novolin R | Insulin Regular, Human | 20 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 20 | suppressed |
| Zileuton Er | Zileuton | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Mitigare | Colchicine | 18 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Xiidra | Lifitegrast | 17 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Calcipotriene-Betamethasone | Calcipotriene/Betamethasone | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 14 |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tolmetin Sodium | Tolmetin Sodium | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diovan | Valsartan | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Isoniazid | Isoniazid | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,205.46 · 91 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CREON, EVENITY, FARXIGA, GEMTESA, IBSRELA, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND, ZTLido | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error